# Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

> **NCT07753720** · PHASE4 · RECRUITING · sponsor: **Al-Azhar University** · enrollment: 260 (estimated)

## Conditions studied

- Erectile Dysfunction
- Tadalafil

## Interventions

- **DRUG:** Tadalafil; Current on-demand PDE5 inhibitor
- **DRUG:** Tadalafil 5 mg

## Key facts

- **NCT ID:** NCT07753720
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753720, "Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07753720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*